H.R. 6561119th CongressIn committeeLatest action Dec 10, 2025Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
HR 6561 funds a CDC-run HPV vaccine awareness campaign at up to $5M/year through 2030, targeting communities with low vaccination or high cancer rates.
65-second read · 5 questions answered below
HR 6561 directs the CDC to run a national public awareness campaign about HPV, a virus linked to six types of cancer including cervical and throat cancer. The campaign would spread accurate information about the HPV vaccine, counter misinformation, and encourage vaccination through social media, TV, radio, and trusted community figures. Grants would go to state, local, and tribal health departments to improve vaccine access and information in underserved communities.
The bill primarily affects public health agencies, doctors, schools, and community organizations that would carry out the campaign. It directly targets families with children ages 9 to 12, adults up to age 45, Black and Hispanic women, people in rural areas, men, and active-duty military members and veterans.
The bill focuses on communities where vaccination rates are low or HPV-related cancer rates are high, which shaped the decision to fund targeted outreach rather than broad general awareness alone. An existing breast and cervical cancer screening program would also see its authorized funding raised to $300 million per year through 2030.
Congress would authorize up to $5 million per year from 2026 through 2030 for the HPV campaign. The existing breast and cervical cancer screening program would have its authorized funding raised to $300 million per year through 2030.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the House Committee on Energy and Commerce.